Imprimis Pharmaceuticals Inc. this month gained the rights to Klarity, a new remedy for dry eye disease (DED).
Richard Lindstrom, who is known for his cataract and refractive surgery expertise, developed Klarity, which is free of preservatives and has the ability to protect the ocular surface after ophthalmic surgery, contact lens use or DED cases.
"The company's commercial capabilities in ophthalmology make them the optimal team to bring this unique dry eye technology to market," said Lindstrom, who will be compensated with royalties and milestone payments, as well as an upfront payment.
He also commented on available solutions for dry eye, claiming that over-the-counter options have the ability to assuage symptoms, but not address more serious conditions.
"We believe our Klarity formulation has the potential to fill an unmet need in current treatment options for patients with moderate and severe DED and it is a privilege to license this important technology from a good friend of our company and a valued member of our Board," Imprimis CEO Mark Baum said.
Between nine and 12 million people in the U.S. suffer from moderate to severe dry eye.
Alerts Sign-up